Treatment of Primary CNS Lymphoma in Patients Receiving Immunosuppressants After Solid Organ Transplantation or for a Chronic Autoimmune Disease
Primary central nervous system lymphoma (PCNSL) presenting in the context of ongoing immunosuppressant therapy poses a distinct clinical challenge. Evidence specific to this sub-population is limited given the rarity of the condition in these settings.
Clinical scenario
This protocol addresses PCNSL arising in patients who are receiving immunosuppressant therapy — either following solid organ transplantation, or for a chronic autoimmune disease. The immunosuppressed state shapes both the risk profile and the available management options.
Treatment approach (overview)
Management in this population involves a careful balance between controlling the lymphoma and preserving graft function or managing the underlying autoimmune condition. A key early step is reduction of immunosuppression, carried out in close collaboration with transplant specialists. Beyond this, systemic chemotherapy is part of the approach — the specific agents and sequencing depend on patient age, performance status, and organ function.
⋯ Full regimen details, agent selection, and dosing guidance in the complete protocol.